Indian Chest Society Unveils Special Booklet On Cough Management

Hyderabad/ Delhi:  The Indian Chest Society (ICS) today unveiled a special booklet titled ‘Guidelines For Cough Management in India’, focusing on the comprehensive management of cough in India. This initiative comes at a crucial time when respiratory health is of paramount concern globally. The special booklet is part of ICS’ medical initiative supported by Dr. Reddy’s Laboratories Limited (Dr. Reddy’s), a global pharmaceutical company headquartered in Hyderabad, India as a scientific partner.

Through this booklet, ICS aims to illuminate the prevalence of cough, explore its diverse causes, and provide insights into its diagnosis and management. With dedicated sections on both dry and wet cough management, considerations regarding red flags, appropriate times for specialist referral, the relevance of fixed-dose combinations (FDCs), and a critical examination of banned FDCs in India, the booklet offers evidence-based strategies for clinicians to tailor their treatment approaches accordingly.

To enhance informed decision-making in clinical practice, the booklet also includes a section on fixed-dose combinations which are better alternatives to codeine-based combinations for managing dry cough, and sheds light on appropriate Beta-2 receptor agonists for wet cough management.

The distinguished panel of eight pulmonologists, comprising Dr. R Vijai Kumar, Vice President of ICS, Dr. Deepak Talwar, Honorary Secretary of ICS, Dr. Pradyut Waghray, Dr. Maulik Sanghvi, Dr. S Z Jafrey, Dr. Mahavir Modi, Dr. Meghana Subhash, and Dr. Visweswaran, has been instrumental in shaping the content of this booklet.

Speaking about the initiative, Dr. R Vijai Kumar from ICS said, “We believe that this initiative will serve as a valuable resource for healthcare professionals across the country, contributing to enhanced patient care and improved outcomes in cough management. We would also like to thank Dr. Reddy’s for providing scientific support.”

The booklet will be available on ICS’ website soon.


About The Indian Chest Society

The Indian Chest Society (ICS) is a not for profit registered society with the Society of Registrars (Registration No. 192-1980, dated 18th July 1980), for Respiratory & Pulmonary and other Physicians with interest in the specialty of Respiratory Medicine. A committee of eminent Chest Physicians, who were also the founding members took up the task to prepare the constitution of the society. The first General Body Meeting was held on 11th September 1981 at Hotel President, Mumbai, and the Constitution was adopted. For more info, please visit- https://www.myicsorg.net/

Related Posts

Cancer cure must not be hostage to Big Pharma

In recent years, immunotherapy has expanded the limits of cancer treatment. Therapies that harness the body’s immune system to fight malignant cells have improved survival rates in cancers once considered…

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Pune:- A woman, 34, dia­gnosed with poly­cystic ovary syn­drome, or PCOS, as a teen­ager, saw her first nat­ural men­strual cycle in Feb­ru­ary—six months after start­ing Moun­jaro for weight man­age­ment. This…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Cancer cure must not be hostage to Big Pharma

Cancer cure must not be hostage to Big Pharma

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients